Tag Archives: HIV

HIV Market Banking on Fixed-Dose Treatments

The HIV markets are expected to grow for the next two years, but major patent expirations in the following years will have a huge impact on pharmaceutical sales by 2019, according to a new report by DataMonitor. Antiretroviral sales in 2009 were estimated at $11.8 billion. While that figure is forecast to hit $14.4 billion […]
Posted in R&D | Also tagged , , , , , , | Leave a comment

TB Alliance Trumpets New, Improved Drugs at World Health Assembly

Like polio and leprosy, developed countries have long since tamed tuberculosis. But even now, other parts of the world continue to struggle against the disease, with nearly all (98 percent) of TB’s 1.7 million worldwide deaths occurring in developing countries. TB’s high comorbidity with HIV infections has recently added another level of urgency to efforts […]
Posted in Corporate Responsibility, Emerging Markets, Global, R&D | Also tagged , , , , , , , , , | Leave a comment

Gilead Making a Bundle

Gilead Sciences has once again proven that independent biotechs can innovate with the best of Big Pharma. The Silicon Valley company’s wizardry at weaving multiple drugs into a single weft enabled it to overthrow GlaxoSmithKline as king of HIV in 2007. Yesterday, at the 16th annual Congress of Retroviruses and Opportunistic Infections (CROI), the biotech […]
Posted in Biotech, Emerging Markets, R&D | Also tagged , , | Leave a comment

Clinton Tinkers With Malaria Market

A team of reporters and camera crews packed into the headquarters of the Clinton Foundation on West 125th Street this afternoon to hear the details of former President Bill Clinton’s plan to tinker with the market for malaria drugs “in a way that has positive implications for the pharmaceutical companies,” he said.
Posted in Corporate Responsibility | Also tagged , , , , , , | 4 Comments
  • Categories

  • Meta